• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

S100B作为拮抗剂干扰由S100A11和RAGE V结构域构成的界面区域。

S100B as an Antagonist To Interfere with the Interface Area Flanked by S100A11 and RAGE V Domain.

作者信息

Dowarha Deepu, Chou Ruey-Hwang, Yu Chin

机构信息

Department of Chemistry, National Tsing Hua University, 101, Section 2, Kuang-Fu Road, Hsinchu 30013, Taiwan.

Graduate Institute of Cancer Biology and Center for Molecular Medicine, China Medical University, No. 91, Hsueh-Shih Road, Taichung 40402, Taiwan.

出版信息

ACS Omega. 2018 Aug 22;3(8):9689-9698. doi: 10.1021/acsomega.8b00922. eCollection 2018 Aug 31.

DOI:10.1021/acsomega.8b00922
PMID:31459098
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6644751/
Abstract

The Ca-sensing protein S100A11 of the S100 family is an important mediator of numerous biological functions and pathological conditions including cancer. The receptor for advanced glycation end products (RAGE) has been well accepted as the major receptor for several S100 family members. Here, we take the S100B protein as an antagonist to interfere with the interaction flanked by S100A11 and the RAGE V domain. We employed NMR spectroscopy to describe the interactions between the S100A11 and S100B proteins. H-N heteronuclear single-quantum correlation-NMR titrations showed the potential binding dynamics of S100A11 and S100B interactions. In the HADDOCK program, we constructed the S100A11-S100B heterodimer complex that was then superimposed with the S100A11-S100B complex structure in the same orientation as the S100A11-RAGE V domain complex. This overlay analysis showed that S100B could interfere in the binding section of S100A11 and the RAGE V domain. Additionally, water-soluble tetrazolium-1 assay provided a functional read-out of the effects of these proteins in an in vitro cancer model. Our study establishes that the development of an S100B antagonist could perform a vital part in the treatment of S100- and RAGE-dependent human diseases.

摘要

S100家族的钙传感蛋白S100A11是包括癌症在内的众多生物学功能和病理状况的重要介质。晚期糖基化终产物受体(RAGE)已被广泛认为是几种S100家族成员的主要受体。在这里,我们以S100B蛋白作为拮抗剂来干扰S100A11与RAGE V结构域之间的相互作用。我们采用核磁共振光谱来描述S100A11和S100B蛋白之间的相互作用。氢-氮异核单量子相关核磁共振滴定显示了S100A11和S100B相互作用的潜在结合动力学。在HADDOCK程序中,我们构建了S100A11-S100B异二聚体复合物,然后将其与S100A11-RAGE V结构域复合物以相同方向叠加S100A11-S100B复合物结构。这种叠加分析表明,S100B可以干扰S100A11与RAGE V结构域的结合区域。此外,水溶性四唑盐-1试验提供了这些蛋白质在体外癌症模型中作用的功能读数。我们的研究表明,S100B拮抗剂的开发可能在治疗S100和RAGE依赖性人类疾病中发挥重要作用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/89d5/6644751/de118436b162/ao-2018-009225_0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/89d5/6644751/bb0b455f5af4/ao-2018-009225_0010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/89d5/6644751/cf58f730285b/ao-2018-009225_0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/89d5/6644751/4d53621b6770/ao-2018-009225_0007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/89d5/6644751/539e0341915f/ao-2018-009225_0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/89d5/6644751/98c572a001d5/ao-2018-009225_0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/89d5/6644751/a23b504a9643/ao-2018-009225_0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/89d5/6644751/d4eb0dd2276c/ao-2018-009225_0008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/89d5/6644751/257e604f275a/ao-2018-009225_0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/89d5/6644751/de118436b162/ao-2018-009225_0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/89d5/6644751/bb0b455f5af4/ao-2018-009225_0010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/89d5/6644751/cf58f730285b/ao-2018-009225_0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/89d5/6644751/4d53621b6770/ao-2018-009225_0007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/89d5/6644751/539e0341915f/ao-2018-009225_0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/89d5/6644751/98c572a001d5/ao-2018-009225_0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/89d5/6644751/a23b504a9643/ao-2018-009225_0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/89d5/6644751/d4eb0dd2276c/ao-2018-009225_0008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/89d5/6644751/257e604f275a/ao-2018-009225_0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/89d5/6644751/de118436b162/ao-2018-009225_0005.jpg

相似文献

1
S100B as an Antagonist To Interfere with the Interface Area Flanked by S100A11 and RAGE V Domain.S100B作为拮抗剂干扰由S100A11和RAGE V结构域构成的界面区域。
ACS Omega. 2018 Aug 22;3(8):9689-9698. doi: 10.1021/acsomega.8b00922. eCollection 2018 Aug 31.
2
Blocking the interface region amongst S100A6 and RAGE V domain via S100B protein.通过 S100B 蛋白阻断 S100A6 和 RAGE V 结构域之间的界面区域。
Biochem Biophys Res Commun. 2020 Dec 10;533(3):332-337. doi: 10.1016/j.bbrc.2020.09.040. Epub 2020 Sep 18.
3
Tranilast Blocks the Interaction between the Protein S100A11 and Receptor for Advanced Glycation End Products (RAGE) V Domain and Inhibits Cell Proliferation.曲尼司特阻断蛋白质S100A11与晚期糖基化终产物受体(RAGE)V结构域之间的相互作用并抑制细胞增殖。
J Biol Chem. 2016 Jul 1;291(27):14300-14310. doi: 10.1074/jbc.M116.722215. Epub 2016 May 12.
4
S100B as an antagonist to block the interaction between S100A1 and the RAGE V domain.S100B作为拮抗剂,可阻断S100A1与晚期糖基化终末产物受体V结构域之间的相互作用。
PLoS One. 2018 Feb 14;13(2):e0190545. doi: 10.1371/journal.pone.0190545. eCollection 2018.
5
Structural insights into the interaction of human S100B and basic fibroblast growth factor (FGF2): Effects on FGFR1 receptor signaling.关于人类S100B与碱性成纤维细胞生长因子(FGF2)相互作用的结构见解:对FGFR1受体信号传导的影响。
Biochim Biophys Acta. 2013 Dec;1834(12):2606-19. doi: 10.1016/j.bbapap.2013.09.012. Epub 2013 Sep 22.
6
Formation of monomeric S100B and S100A11 proteins at low ionic strength.在低离子强度下形成单体S100B和S100A11蛋白。
Biochemistry. 2009 Mar 10;48(9):1954-63. doi: 10.1021/bi802086a.
7
The Trp triad within the V-domain of the receptor for advanced glycation end products modulates folding, stability and ligand binding.V 域内的色氨酸三联体调节晚期糖基化终产物受体的折叠、稳定性和配体结合。
Biosci Rep. 2020 Jan 31;40(1). doi: 10.1042/BSR20193360.
8
Structural insights into the binding of the human receptor for advanced glycation end products (RAGE) by S100B, as revealed by an S100B-RAGE-derived peptide complex.由S100B-RAGE衍生肽复合物揭示的S100B与人晚期糖基化终产物受体(RAGE)结合的结构见解。
Acta Crystallogr D Biol Crystallogr. 2015 May;71(Pt 5):1176-83. doi: 10.1107/S1399004715004216. Epub 2015 Apr 25.
9
Inflammation-induced chondrocyte hypertrophy is driven by receptor for advanced glycation end products.炎症诱导的软骨细胞肥大由晚期糖基化终末产物受体驱动。
J Immunol. 2005 Dec 15;175(12):8296-302. doi: 10.4049/jimmunol.175.12.8296.
10
Blocking the interaction between S100A9 and RAGE V domain using CHAPS molecule: A novel route to drug development against cell proliferation.使用CHAPS分子阻断S100A9与RAGE V结构域之间的相互作用:一种针对细胞增殖的药物开发新途径。
Biochim Biophys Acta. 2016 Nov;1864(11):1558-69. doi: 10.1016/j.bbapap.2016.08.008. Epub 2016 Aug 12.

引用本文的文献

1
The Anti-Cancer Activity of Pentamidine and Its Derivatives (WLC-4059) Is through Blocking the Interaction between S100A1 and RAGE V Domain.戊二脒及其衍生物(WLC-4059)的抗癌活性是通过阻断 S100A1 与 RAGE V 结构域的相互作用实现的。
Biomolecules. 2022 Dec 30;13(1):81. doi: 10.3390/biom13010081.
2
The Calcium Binding Protein S100A11 and Its Roles in Diseases.钙结合蛋白S100A11及其在疾病中的作用。
Front Cell Dev Biol. 2021 Jun 11;9:693262. doi: 10.3389/fcell.2021.693262. eCollection 2021.
3
Lysozyme as the anti-proliferative agent to block the interaction between S100A6 and the RAGE V domain.

本文引用的文献

1
Tranilast Blocks the Interaction between the Protein S100A11 and Receptor for Advanced Glycation End Products (RAGE) V Domain and Inhibits Cell Proliferation.曲尼司特阻断蛋白质S100A11与晚期糖基化终产物受体(RAGE)V结构域之间的相互作用并抑制细胞增殖。
J Biol Chem. 2016 Jul 1;291(27):14300-14310. doi: 10.1074/jbc.M116.722215. Epub 2016 May 12.
2
The HADDOCK2.2 Web Server: User-Friendly Integrative Modeling of Biomolecular Complexes.HADDOCK2.2 网页服务器:生物分子复合物的用户友好型综合建模
J Mol Biol. 2016 Feb 22;428(4):720-725. doi: 10.1016/j.jmb.2015.09.014. Epub 2015 Sep 26.
3
RAGE and its ligands in cancer - culprits, biomarkers, or therapeutic targets?
溶菌酶作为一种抗增殖剂,阻断 S100A6 与 RAGE V 结构域的相互作用。
PLoS One. 2019 May 9;14(5):e0216427. doi: 10.1371/journal.pone.0216427. eCollection 2019.
癌症中的RAGE及其配体——罪魁祸首、生物标志物还是治疗靶点?
Neoplasma. 2015;62(3):353-64. doi: 10.4149/neo_2015_061.
4
Knockdown of S100A11 expression suppresses ovarian cancer cell growth and invasion.敲低S100A11表达可抑制卵巢癌细胞的生长和侵袭。
Exp Ther Med. 2015 Apr;9(4):1460-1464. doi: 10.3892/etm.2015.2257. Epub 2015 Feb 3.
5
S100A3 suppression inhibits in vitro and in vivo tumor growth and invasion of human castration-resistant prostate cancer cells.S100A3抑制可抑制人去势抵抗性前列腺癌细胞的体外和体内肿瘤生长及侵袭。
Urology. 2015 Jan;85(1):273.e9-15. doi: 10.1016/j.urology.2014.09.018. Epub 2014 Nov 13.
6
Co-expression of RAGE and HMGB1 is associated with cancer progression and poor patient outcome of prostate cancer.RAGE 和 HMGB1 的共表达与前列腺癌的肿瘤进展和患者预后不良相关。
Am J Cancer Res. 2014 Jul 16;4(4):369-77. eCollection 2014.
7
RAGE mediates S100A4-induced cell motility via MAPK/ERK and hypoxia signaling and is a prognostic biomarker for human colorectal cancer metastasis.RAGE通过MAPK/ERK和缺氧信号传导介导S100A4诱导的细胞运动,并且是人类结直肠癌转移的预后生物标志物。
Oncotarget. 2014 May 30;5(10):3220-33. doi: 10.18632/oncotarget.1908.
8
S100A6 as a potential serum prognostic biomarker and therapeutic target in gastric cancer.S100A6 作为胃癌潜在的血清预后生物标志物和治疗靶点。
Dig Dis Sci. 2014 Sep;59(9):2136-44. doi: 10.1007/s10620-014-3137-z. Epub 2014 Apr 5.
9
Expression and subcellular localization of RAGE in melanoma cells.RAGE 在黑素瘤细胞中的表达与亚细胞定位。
Biochem Cell Biol. 2014 Apr;92(2):127-36. doi: 10.1139/bcb-2013-0064. Epub 2014 Mar 31.
10
S100P antibody-mediated therapy as a new promising strategy for the treatment of pancreatic cancer.S100P 抗体介导的治疗作为一种治疗胰腺癌的新的有前途的策略。
Oncogenesis. 2014 Mar 17;3(3):e92. doi: 10.1038/oncsis.2014.7.